
Nomi2.5 mg
Square Pharmaceuticals PLC.
Zolmitriptan is FDA-approved for the acute treatment of migraine with or without aura in adults.
Zolmitriptan is FDA-approved for the acute treatment of migraine with or without aura in adults. It is used to relieve an ongoing migraine attack, not to reduce the number of attacks a patient has.
Zolmitriptan is not indicated for the prevention (prophylaxis) of migraine, and is not indicated for cluster headache, tension-type headache, or other headache types not clearly diagnosed as migraine. There is no well-established off-label use of Zolmitriptan that is commonly recommended in guidelines.
The dosing of Zolmitriptan is individualized based on indication and patient factors, as summarized below.
| Population/Situation | Recommended Dosing of Zolmitriptan |
|---|---|
| Adults - initial dose | 2.5 mg (or 1.25 mg in patients who may be more sensitive) taken orally at the onset of a migraine attack |
| Adults - repeat dosing | If migraine returns or the first dose was only partially effective, a second dose may be taken at least 2 hours after the first |
| Maximum single dose | 5 mg |
| Maximum total daily dose | 10 mg within 24 hours |
| Hepatic impairment (moderate-severe) | Limit single dose to 1.25 mg; maximum 5 mg/day in severe impairment (see Precautions) |
| Concurrent cimetidine use | Maximum single dose 2.5 mg; maximum daily dose 5 mg (see Interactions) |
| Pediatric use | Not recommended; safety and efficacy not established (see Pediatric Uses) |
Zolmitriptan should be taken as soon as possible after migraine symptoms begin, but is effective when administered at any stage of an attack. It should not be used to prevent an attack before symptoms start.
Common side effects of Zolmitriptan (occurring in approximately 5% or more of patients and more often than with placebo) include:
Serious but rare side effects include myocardial infarction, other cardiac arrhythmias, coronary artery vasospasm, stroke, serotonin syndrome (especially with concurrent SSRIs/SNRIs; see Interactions), and anaphylaxis/hypersensitivity reactions. Patients experiencing chest pain, severe dizziness, sudden weakness, or signs of an allergic reaction after taking Zolmitriptan should seek immediate medical attention.
Zolmitriptan is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.